CARsgen Therapeutics Holdings マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Zonghai Li

最高経営責任者

CN¥2.1m

報酬総額

CEO給与比率	50.2%
CEO在任期間	3.8yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO報酬分析

CARsgen Therapeutics Holdings の収益と比較して、Zonghai Li の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-CN¥695m
Mar 31 2024	n/a	n/a	-CN¥721m
Dec 31 2023	CN¥2m	CN¥1m	-CN¥748m
Sep 30 2023	n/a	n/a	-CN¥834m
Jun 30 2023	n/a	n/a	-CN¥920m
Mar 31 2023	n/a	n/a	-CN¥906m
Dec 31 2022	CN¥2m	CN¥1m	-CN¥892m

報酬と市場: Zonghaiの総報酬 ($USD 287.63K ) は、 Hong Kong市場 ($USD 392.73K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Zonghaiの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Zonghai Li (50 yo)

3.8yrs

在職期間

CN¥2,084,000

報酬

Dr. Zonghai Li M.D., Ph D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 & Chairman of the Board. He ser...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Zonghai Li	Co-Founder	3.8yrs	CN¥2.08m	データなし
Huamao Wang	Co-Founder	3.8yrs	CN¥2.11m	データなし
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	データなし
Hong Ma	Senior Vice President of Clinical Development	no data	データなし	データなし
Leigh Hsu	Senior Vice President of Business Development	no data	データなし	データなし
Raffaele Baffa	Chief Medical Officer	2.6yrs	データなし	データなし
Sylvie Peltier	Senior Vice President of Global Regulatory Affairs	2.1yrs	データなし	データなし
Wing Yat Lui	Company Secretary	3.8yrs	データなし	データなし

3.2yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: 2171の経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Zonghai Li	Co-Founder	6.8yrs	CN¥2.08m	データなし
Huamao Wang	Co-Founder	6.2yrs	CN¥2.11m	データなし
Hua Jiang	Executive Director	2.3yrs	CN¥1.39m	データなし
Ronggang Xie	Non-Executive Director	4.2yrs	データなし	データなし
Xiangke Zhao	Independent Non-Executive Director	1.3yrs	CN¥80.00k	データなし
Bingsen Guo	Non-Executive Director	6.2yrs	データなし	1.62% HK$ 62.4m
Guangmei Yan	Independent Non-Executive Director	3.4yrs	CN¥222.00k	データなし
Huaqing Guo	Non-Executive Director	4.2yrs	データなし	0.38% HK$ 14.6m
Wen Zhou	Independent Non-Executive Director	less than a year	データなし	データなし

4.2yrs

平均在職期間

47yo

平均年齢

経験豊富なボード: 2171の取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

CARsgen Therapeutics Holdings マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Non-Executive Director recently bought HK$903k worth of stock

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Recent updates

New major risk - Share price stability

CARsgen Therapeutics Holdings Limited Announces That the U.S. Food and Drug Administration (FDA) Loses the Clinical Holds on Clinical Trials of Zevor-Ccel

Carsgen Therapeutics Holdings Limited Submits Application to Request Lifting Clinical Holds to FDA

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New major risk - Share price stability

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34